Breaking News

ICON Names Chairman

By Gil Roth | December 26, 2012

Lynch ascends to top role

Thomas Lynch has been appointed as chairman of the board of ICON plc. His term begins on January 1, 2013. Mr. Lynch has served as a non-executive director of ICON since January 1996 and as chairman of its Audit, Compensation and Nominations Committees as well as Lead Independent Director since December 2009.

Mr. Lynch served as chairman and chief executive officer of Amarin Corp. from December 2007 through December 2009 during which time he re-purposed and refinanced the company toward the development of Vascepa for hypertriglyceridemia and dislipidemia. Mr Lynch retired from the board of Amarin in October 2010 but continues as chairman of Amarin Pharmaceuticals Ireland Ltd.

Mr. Lynch served in a variety of senior roles in Elan Corporation plc from 1993 to 2004. He was a director of IDA Ireland from 2001-2010 and of the Royal Opera House (Covent Garden) from 2001-2010. He currently serves as a director of GW Pharmaceuticals, is chairman of Dublin Academic Medical Centre, and the Queens University of Belfast Foundation. He also serves as a board member of a number of public and privately held pharmaceutical companies.

Mr. Lynch commented, “I am very pleased to assume the role of chairman at this time of great opportunity for ICON. I would like to thank Dr. Bruce Given, my predecessor, for his contribution as chairman over the last three years. I look forward to working with my Board colleagues and the executive team to help ICON continue to grow and enhance its position as the global partner of choice in the CRO industry.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks